These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34354111)

  • 1. Conformational dynamics of androgen receptors bound to agonists and antagonists.
    Gim HJ; Park J; Jung ME; Houk KN
    Sci Rep; 2021 Aug; 11(1):15887. PubMed ID: 34354111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
    Liu H; An X; Li S; Wang Y; Li J; Liu H
    Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.
    Azhagiya Singam ER; Tachachartvanich P; La Merrill MA; Smith MT; Durkin KA
    J Phys Chem B; 2019 Sep; 123(36):7657-7666. PubMed ID: 31431014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
    Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
    Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling.
    Duan M; Liu N; Zhou W; Li D; Yang M; Hou T
    J Chem Theory Comput; 2016 Sep; 12(9):4611-9. PubMed ID: 27560203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.
    Qu F; Gu Y; Wang Q; He M; Zhou F; Sun J; Wang G; Peng Y
    Invest New Drugs; 2020 Oct; 38(5):1292-1302. PubMed ID: 32008178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator.
    Liu N; Zhou W; Guo Y; Wang J; Fu W; Sun H; Li D; Duan M; Hou T
    J Chem Inf Model; 2018 Aug; 58(8):1652-1661. PubMed ID: 29993249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation.
    Chen H; Zhou Y; Wang X; Chai X; Wang Z; Wang E; Xu L; Hou T; Li D; Duan M
    Adv Sci (Weinh); 2024 May; 11(19):e2309261. PubMed ID: 38481034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Al-Zobaidy MJ; Akeel Al-Hussaniy H; S Al-Tameemi Z
    F1000Res; 2022; 11():516. PubMed ID: 38779468
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer.
    Osguthorpe DJ; Hagler AT
    Biochemistry; 2011 May; 50(19):4105-13. PubMed ID: 21466228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
    Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
    Doamekpor SK; Peng P; Xu R; Ma L; Tong Y; Tong L
    Acta Crystallogr F Struct Biol Commun; 2023 Apr; 79(Pt 4):95-104. PubMed ID: 36995121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
    Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
    Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An insight about the mechanism of action (MoA) of R-bicalutamide on the androgen receptor homodimer using molecular dynamic.
    Cavaliere F; Cozzini P
    Toxicol Appl Pharmacol; 2022 Apr; 440():115953. PubMed ID: 35245614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.